| abstract |
The present invention relates to novel compounds having ([1,3]thiazolo[5,4- b]pyridine-2-yl)-2-carboxamide structure, as being illustrated in Formula 1, for inhibition of angiogenesis receptor tyrosine kinases, in particular, VEGF receptor 2 kinase ('KDR') activity, methods for preparing the same, their use and a pharmaceutical composition comprising thereapeutically effective amount of the said compounds. The compounds according to the present invention are useful for the treatment and prevention of angiogenesis-related diseases, particularly resulting from the unregulated or undesired KDR activity, such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy, etc. |